Phacilitate Non-dilutive Funding Sources for Advanced Therapy Biotechs

Non-dilutive Funding Sources for Advanced Therapy Biotechs

A comprehensive report examining non-dilutive funding applications that are currently open or opening soon, in partnership with FreeMind
The funding landscape for advanced therapies is currently booming, with a late 2018 IPO from Moderna breaking records at $640 million. 2019’s top IPO came close to topping this at $505 million for Genmab and 2020’s biggest IPO so far goes to China’s Legend Bio, who raised $424 million from 18.3 million shares after presenting their latest data at ASCO.
 
Similarly, AdaptImmune’s presentation of phase I data for its TCR therapy ADP-A2M4 saw an investment of $226m in the weeks following the conference.
 
However, the big headlines and stories we read are more often than not about dilutive sources of funding; VCs, capital investments, licensing deals etc. What’s the price of this for early-stage biotechs?
 
Phacilitate Non-dilutive Funding Sources for Advanced Therapy Biotechs

 
Non-dilutive funding sources, such as grants and loans, allow smaller companies and start-ups to retain their value and control. Non-dilutive funding also means that start-ups and early-stage biotechs can mature and progress to a point of gaining experience and becoming a more attractive prospect when the time for dilutive levels of funding are needed.
 
There can be some downsides, grants can be restrictive in terms of their geography and eligibility criteria, as well as being time-sensitive. Biotechs will also find there is a lot of competition from Universities for the same grants.
 
This report will examine some of the non-dilutive funding applications that are currently opening or that will be opening soon.
 
Phacilitate Non-dilutive Funding Sources for Advanced Therapy Biotechs